Serious Adverse Event (SAE)

In Detail

A serious adverse event (SAE) is a specific category of adverse event that meets one or more of the following criteria defined by the FDA and international regulatory bodies: it results in death, is life-threatening, requires hospitalization or prolongs an existing hospitalization, causes persistent or significant disability or incapacity, results in a congenital anomaly or birth defect, or requires medical intervention to prevent one of these outcomes. SAEs are subject to expedited reporting requirements — sponsors must report them to the FDA within 15 calendar days (or 7 days for fatal or life-threatening events). The distinction between an adverse event and a serious adverse event is important because it determines the level of regulatory scrutiny and reporting urgency. Not all severe adverse events are serious (a severe headache, while unpleasant, does not typically meet SAE criteria), and not all serious adverse events are severe (elective hospitalization for a minor procedure could qualify as an SAE). The Data Safety Monitoring Board reviews all SAEs to determine whether they represent a pattern that requires action, such as modifying the protocol, adding safety warnings, or stopping the trial entirely. SAE data is a critical component of the safety database submitted to the FDA as part of the New Drug Application. For participants, knowing how SAEs are handled provides reassurance that rigorous safety monitoring is in place throughout every clinical trial.